Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021
March 1, 2021
Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease
February 16, 2021
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update
February 9, 2021
Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast
January 15, 2021
Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease
December 7, 2020
Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020
November 19, 2020
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update
November 11, 2020
Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
November 11, 2020
Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast
October 23, 2020
Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19
October 21, 2020

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe